research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
Search
for
Did you mean Janus Kinase 3 Inhibitor?
Sort by
Research
30 / 1000+ results 
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Peripheral Neuropathy Associated with Tofacitinib Use in Alopecia Universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Emerging Drugs for Alopecia Areata: JAK Inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Hair Follicle Reconstruction and Stem Cells
Stem cells could improve hair growth and new treatments for baldness are being researched.
research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients
Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Baricitinib as a Treatment for Myasthenia Gravis: A Case Report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Conventional and Novel Stem Cell-Based Therapies for Androgenic Alopecia
Stem cell technologies and regenerative medicine, including platelet-rich plasma, show promise for hair restoration in treating hair loss, but more research is needed.
research Gynostemma Pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth via the Wnt/Beta-Catenin Pathway
Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Retrospective Cohort Study of 90 Patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research The Experts Meetings on Psoriasis: Recommendations for Daily Practice
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Alopecia Areata: Comprehensive Overview and Management
The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Fzd2 Controls Multiple Aspects of Epidermal Development Through Distinct Signaling Mechanisms
Fzd2 is important for skin and hair development through various signaling ways.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.